

 Early Warning System

EIB-20240557

BIOVET RDI PROGRAMME



Quick Facts

Countries	Bulgaria
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2025-05-15
Borrower	Biovet AD; Huvepharma EOOD
Sectors	Agriculture and Forestry, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 145.50 million
Loan Amount (USD)	\$ 145.50 million
Project Cost (USD)	\$ 313.38 million



Project Description

According to the EIB, the project will finance research, development, and innovation (RDI) investments by Biovet AD and Huvepharma EOOD (the Borrowers) in Bulgaria and other EU Member States.

The aim is to support the borrowers' RDI investments in feed additives, complex veterinary pharmaceutical products and vaccines. Improving animal health enhances food safety, reduces antibiotic resistance by promoting the use of vaccines, and supports sustainable livestock production. It also contributes to the expansion of EU-based animal health manufacturing.



Investment Description

- European Investment Bank (EIB)



Private Actors Description

As stated on the company's website, Huvepharma is a fast-growing global pharmaceutical company with a focus on developing, manufacturing and marketing human health and animal health and nutrition products.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Huvepharma AD Sofia	Client	Industry and Trade



Contact Information

No project contacts provided at the time of disclosure.

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet \(ESDS\)](#)



Other Related Projects

- EIB-20220093 PAN-EUROPEAN INNOVATION LENDING ENVELOPE I